(RxWiki News) The US Food and Drug Administration (FDA) has approved a new ultra-rapid-acting insulin.
This new approval is for Lyumjev (insulin lispro-aabc injection), which the FDA approved to lower blood sugar levels in adults with type 1 and type 2 diabetes.
This drug is to be injected under the skin and is available in two doses: 100 and 200 units/mL.
This new insulin, produced by the pharmaceutical company Lilly, was developed to allow for faster absorption into the bloodstream. In fact, its formulation is based on Humalog (insulin lispro), which is also made by Lilly.
Its main competitor is likely to be Novo Nordisk's fast-acting insulin Fiasp (insulin aspart).
As of publishing time, this new insulin was not approved to treat children or be used in insulin pumps.
Because this is a rapid-acting insulin, it is to be injected at the beginning of a meal or within 20 minutes after you start eating a meal.
Eli Lilly said it plans to include this new insulin in the Lilly Insulin Value Program, which helps with the affordability of the medication. Anyone with commercial insurance and those without insurance can fill their monthly prescription of Lyumjev for $35.
Common side effects of this insulin include low blood sugar, reactions at the injection site, skin thickening at the injection site, itching, rash, weight gain and allergic reactions.
This new approval was granted to Eli Lilly.
